NCT05686239: An ongoing trial by Recognify Life Sciences
This trial is ongoing. It must report results 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05686239 |
|---|---|
| Title | An Adaptive, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 8, 2022 |
| Completion date | April 9, 2025 |
| Required reporting date | April 9, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |